Gaucher Disease Type 3 Latest Advances

Crossing the barrier: nanomedicine as a frontier therapy for neuropathic Gaucher disease type 3.

Journal: Annals of medicine and surgery (2012)

Published: October 19, 2025

Microbiome-gut-heart axis in cardiac complications of Gaucher disease type 3.

Journal: Annals of medicine and surgery (2012)

Published: October 01, 2025

Case Report: Novel treatment approach for severe interstitial lung disease in type 3 Gaucher disease.

Journal: Frontiers in pediatrics

Published: April 01, 2025

Product Development of High-Dose Ambroxol HCl Capsules for an n-of-1 Clinical Trial Involving Dutch Patients with Gaucher Disease Type 3.

Journal: Pharmaceutics

Published: February 26, 2025

Gaucher disease type 3: Classification of the chronic neuronopathic variant informed by genotype in a phenotypically diverse cohort.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: August 21, 2024

Pediatric Gaucher Disease Type 3 Presenting with Oculomotor Apraxia: A Case Report.

Journal: Children (Basel, Switzerland)

Published: July 03, 2024

Gaucher disease type 3 from infancy through adulthood: a conceptual model of signs, symptoms, and impacts associated with ataxia and cognitive impairment.

Journal: Orphanet journal of rare diseases

Published: June 12, 2024

Histologic and ultrastructural study of intracranial Gaucheroma causing deafness in a patient with Gaucher disease type 3: Effects of substrate reduction therapy.

Journal: Molecular genetics and metabolism reports

Published: January 29, 2024

Hematopoietic stem cell transplantation or enzyme replacement therapy in Gaucher disease type 3.

Journal: Molecular genetics and metabolism

Published: December 22, 2023

A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.

Journal: Acta neurologica Belgica

Published: October 07, 2023

Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Journal: Blood cells, molecules & diseases

Published: July 18, 2022

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.

Journal: Molecular genetics and metabolism reports

Published: April 08, 2022